# New Funding to Support SER-252 Trial in Advanced Parkinson’s > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/synthetic-cannabinoid-parkinsons-trial-ser-252-funding/ > **Published:** 2026-03-27T16:04:54-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:19:12-04:00 > **Clinical Summary:** Explore the synthetic cannabinoid Parkinsons trial SER-252, a promising approach for managing levodopa-induced dyskinesia in advanced Parkinson's disease. --- ✦ New CED Clinical Relevance  #80High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic Parkinson’S DiseaseMovement DisordersSynthetic CannabinoidsDyskinesia[Clinical Trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) Why This Matters Novel cannabinoid therapeutics targeting specific Parkinson’s motor symptoms represent a potentially significant advancement in managing levodopa-induced dyskinesia, which affects up to 95% of patients after 10 years of treatment. If SER-252 demonstrates efficacy, it could provide clinicians with a precision tool for addressing one of Parkinson’s most challenging complications. Clinical Summary SER-252 is a synthetic cannabinoid being evaluated for levodopa-induced dyskinesia in advanced Parkinson’s disease. The compound appears designed to target specific [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) involved in motor control pathways, though the exact mechanism and receptor selectivity remain proprietary. Levodopa-induced dyskinesia represents involuntary movements that develop as a consequence of long-term dopamine replacement therapy, creating a clinical challenge where the treatment becomes part of the problem. Current management options are limited and often require complex medication adjustments or surgical interventions. Dr. Caplan’s Take “I’m cautiously optimistic about targeted cannabinoid approaches to movement disorders, but we need to see the actual trial data before drawing conclusions about efficacy or safety. The Parkinson’s community has seen many promising compounds fail to translate from preclinical models to meaningful patient benefit.” Clinical Perspective 🧠 Clinicians managing advanced Parkinson’s patients should monitor this trial’s progress, as dyskinesia management remains one of our most challenging therapeutic problems. Until we have Phase II/III data, standard approaches including amantadine, medication timing adjustments, and deep brain stimulation consultation remain our evidence-based options. This represents the broader potential for precision [cannabinoid medicine](https://cedclinic.com/cannabinoids-prostate-cancer-anti-tumor-drugs/), but patients should understand we’re still in early investigational phases. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20New%20funding%20to%20support%20SER-252%20trial%20in%20advanced%20Parkinson%27s%20%40drcaplan&url=https%3A//parkinsonsnewstoday.com/news/new-funding-support-ser-252-trial-advanced-parkinsons/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//parkinsonsnewstoday.com/news/new-funding-support-ser-252-trial-advanced-parkinsons/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20New%20funding%20to%20support%20SER-252%20trial%20in%20advanced%20Parkinson%27s%20--%20via%20%40drcaplan.bsky.social%20https%3A//parkinsonsnewstoday.com/news/new-funding-support-ser-252-trial-advanced-parkinsons/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://parkinsonsnewstoday.com/news/new-funding-support-ser-252-trial-advanced-parkinsons/](https://parkinsonsnewstoday.com/news/new-funding-support-ser-252-trial-advanced-parkinsons/) Table of Contents - [FAQ](#FAQ)[What is the connection between cannabis and Parkinson’s disease treatment?](#What_is_the_connection_between_cannabis_and_Parkinson8217s_disease_treatment) - [What are synthetic cannabinoids and how do they differ from natural cannabis?](#What_are_synthetic_cannabinoids_and_how_do_they_differ_from_natural_cannabis) - [Can cannabis help with dyskinesia in Parkinson’s patients?](#Can_cannabis_help_with_dyskinesia_in_Parkinson8217s_patients) - [What movement disorders besides Parkinson’s might benefit from cannabis treatment?](#What_movement_disorders_besides_Parkinson8217s_might_benefit_from_cannabis_treatment) - [Is cannabis-based treatment for Parkinson’s disease currently available to patients?](#Is_cannabis-based_treatment_for_Parkinson8217s_disease_currently_available_to_patients) - [Related](#Related) ## FAQ #### What is the connection between cannabis and Parkinson’s disease treatment? Cannabis, particularly synthetic cannabinoids, is being studied as a potential treatment for Parkinson’s disease symptoms. Research focuses on how cannabinoids may help manage movement disorders and dyskinesia associated with the condition. #### What are synthetic cannabinoids and how do they differ from natural cannabis? Synthetic cannabinoids are laboratory-created compounds that mimic the effects of natural [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/). They offer more precise dosing and standardized effects compared to plant-based cannabis, making them potentially more suitable for medical applications. #### Can cannabis help with dyskinesia in Parkinson’s patients? Emerging research suggests that certain cannabinoids may help reduce dyskinesia, which are involuntary movements that often occur as a side effect of long-term Parkinson’s medication use. However, more clinical studies are needed to establish definitive treatment protocols. #### What movement disorders besides Parkinson’s might benefit from cannabis treatment? Cannabis is being investigated for various movement disorders including essential tremor, dystonia, and Huntington’s disease. The anti-inflammatory and neuroprotective properties of cannabinoids may provide therapeutic benefits across multiple neurological conditions. #### Is cannabis-based treatment for Parkinson’s disease currently available to patients? While some jurisdictions allow medical cannabis for Parkinson’s disease, treatment availability varies by location and regulation. Patients should consult with healthcare providers familiar with [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) to discuss potential benefits and risks. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “New funding to support SER-252 trial in advanced Parkinson’s”, “url”: “https://parkinsonsnewstoday.com/news/new-funding-support-ser-252-trial-advanced-parkinsons/”, “datePublished”: “2026-03-27T14:31:42Z”, “about”: “new funding support ser 252 trial”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cell therapy eases Parkinson's motor symptoms in early trial](https://cedclinic.com/cell-therapy-parkinsons-disease-motor-symptoms-trial/) Discover how cell therapy is showing promise in alleviating motor symptoms in Parkinson's disease during early [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/). [Read More](https://cedclinic.com/cell-therapy-parkinsons-disease-motor-symptoms-trial/) Pirepemat shows promise in trial for reducing risk of falls in Parkinson's Learn about Pirepemat's potential to reduce fall risk in Parkinson's patients, highlighting advances in symptom management. Explore Study [Two compounds found in cannabis plant reverse liver disease damage, study suggests](https://cedclinic.com/cannabis-compounds-reverse-liver-damage-study/) A recent study suggests cannabis-derived compounds may reverse liver disease damage, expanding therapeutic possibilities. [Discover More](https://cedclinic.com/cannabis-compounds-reverse-liver-damage-study/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).